Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and flexible dosage forms of nanoformed drug substances. It also offers STARMAP, an online platform to pick winners among candidate molecules for CESS powered nanoforming. The company was founded in 2008 and is headquartered in Helsinki, Finland.

Sector

Healthcare

Industry

Biotechnology

CEO

Haeggstrom, Edward

Employees

173

Website

www.nanoform.com

IPO Date

2020-06-04

Headquarters

Cultivator II, Viikinkaari 4, Helsinki, Uusimaa, 00790, Finland

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Nanoform Finland NANOFH

Nanoform Finland Earnings Call Summary

Nanoform Finland Earnings

Transcripts

Events

About Nanoform Finland Oyj

Nanoform Finland
NANOFH